Schaper Benz & Wise Investment Counsel Inc. WI Acquires New Holdings in Danaher Corporation $DHR

Schaper Benz & Wise Investment Counsel Inc. WI bought a new position in shares of Danaher Corporation (NYSE:DHR) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 64,715 shares of the conglomerate’s stock, valued at approximately $14,338,000.

Several other institutional investors also recently modified their holdings of DHR. BlackRock Inc. acquired a new stake in shares of Danaher during the 2nd quarter valued at $10,492,520,000. Jupiter Topco LLC acquired a new position in Danaher in the 2nd quarter worth about $1,456,317,000. Generation Investment Management LLP bought a new position in Danaher in the second quarter valued at about $1,287,949,000. Bank of America Corp DE acquired a new stake in shares of Danaher during the second quarter valued at about $993,846,000. Finally, Legal & General Group Plc acquired a new stake in shares of Danaher during the second quarter valued at about $801,056,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on DHR shares. TD Cowen lowered their price objective on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Barclays boosted their target price on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday. Guggenheim upped their price target on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Royal Bank Of Canada raised their price target on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Evercore reiterated an “outperform” rating and set a $230.00 price target on shares of Danaher in a report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $235.23.

Danaher Price Performance

Danaher stock opened at $220.15 on Friday. The stock’s 50 day moving average is $211.38 and its 200 day moving average is $194.62. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The firm has a market cap of $154.76 billion, a P/E ratio of 39.10, a P/E/G ratio of 2.71 and a beta of 0.76. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.77 earnings per share. As a group, research analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is currently 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.